{"id":"ceftolozane-tazobactam-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Clostridioides difficile infection"}]},"_chembl":{"chemblId":"CHEMBL1213250","moleculeType":"Small molecule","molecularWeight":"764.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftolozane is a fifth-generation cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall formation. Tazobactam is a beta-lactamase inhibitor that protects ceftolozane from degradation by bacterial beta-lactamases, extending its spectrum of activity against resistant gram-negative organisms including Pseudomonas aeruginosa and Enterobacteriaceae.","oneSentence":"Ceftolozane-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:50.564Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) including pyelonephritis"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"},{"name":"Complicated intra-abdominal infections (cIAI)"}]},"trialDetails":[{"nctId":"NCT04223752","phase":"PHASE1","title":"Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-04-17","conditions":"Nosocomial Pneumonia","enrollment":41},{"nctId":"NCT06422533","phase":"NA","title":"Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-11-07","conditions":"Hematologic Neoplasms, Neutropenia","enrollment":226},{"nctId":"NCT06035055","phase":"PHASE4","title":"Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis","status":"UNKNOWN","sponsor":"Sunshine Coast Hospital and Health Service","startDate":"2023-10","conditions":"Bronchiectasis, Cystic Fibrosis, Pseudomonas Aeruginosa","enrollment":30},{"nctId":"NCT05061654","phase":"PHASE4","title":"CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients","status":"WITHDRAWN","sponsor":"Hamad Medical Corporation","startDate":"2022-08","conditions":"Neutropenia, Febrile, Hematologic Cancer","enrollment":""},{"nctId":"NCT03217136","phase":"PHASE2","title":"MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-03","conditions":"Complicated Intra-Abdominal Infection","enrollment":94},{"nctId":"NCT03230838","phase":"PHASE2","title":"MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-26","conditions":"Complicated Urinary Tract Infection, Pyelonephritis","enrollment":134},{"nctId":"NCT03830333","phase":"PHASE3","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-20","conditions":"Complicated Intra-abdominal Infections","enrollment":268},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726},{"nctId":"NCT02387372","phase":"PHASE1","title":"Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-02-05","conditions":"Critically Ill, Pneumonia","enrollment":37},{"nctId":"NCT02728089","phase":"PHASE3","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-14","conditions":"Urinary Tract Infection (UTI), Complicated Urinary Tract Infection, Pyelonephritis","enrollment":115},{"nctId":"NCT01853982","phase":"PHASE3","title":"Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2013-06-14","conditions":"Ventilator-Associated Pneumonia (VAP)","enrollment":4},{"nctId":"NCT01147640","phase":"PHASE2","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06-25","conditions":"Complicated Intra-abdominal Infection","enrollment":122},{"nctId":"NCT02739997","phase":"PHASE3","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-08","conditions":"Intra-abdominal Infection, Complicated Intra-abdominal Infection","enrollment":100},{"nctId":"NCT02508753","phase":"PHASE1","title":"Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06","conditions":"Healthy","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zerbaxa"],"phase":"marketed","status":"active","brandName":"Ceftolozane-tazobactam IV","genericName":"Ceftolozane-tazobactam IV","companyName":"Hamad Medical Corporation","companyId":"hamad-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftolozane-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation. Used for Complicated urinary tract infections (cUTI) including pyelonephritis, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Complicated intra-abdominal infections (cIAI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}